Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Sherven Sharma, Ph.D.
Sherven Sharma, Ph.D.

Affiliation(s):

Professor, Department of Medicine, Pulmonary and Critical Care
Director of Molecular Medicine, Veterans Affairs Greater Los Angeles Healthcare System
Member, California NanoSystems Institute (CNSI)
Member, JCCC Tumor Immunology Program Area

Contact Information:

Phone:
(310) 478-3711 ext. 41863
Email:
ssharma@mednet.ucla.edu

Scientific Interest(s):

Research in Dr. Sherven Sharma's laboratory is geared toward unraveling the mechanisms in the tumor microenvironment that evade host responses and promote and maintain lung tumor growth. Knowledge gained from tumor host interactions is utilized for the development of novel cellular and nanocapsule platform-based immune strategies for lung cancer therapy.

Selected Cancer-Related Publications:

Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009 Jun 1;182(11):6951-8.

Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006 Mar 15;66(6):3205-13.

Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett SM. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006 May 15;66(10):5338-45.

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005 Jun 15;65(12):5211-20.

Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol. 2005 Jul 15;175(2):813-9.

In the News: